Miami, FL, May 15, 2003
Noven Announces Annual Meeting Results; Diane M. Barrett Appointed Chief Financial Officer
-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN), ) today announced the results of its 2003 Annual Meeting of Shareholders and the appointment of Diane M. Barrett (previously Noven’s Vice President – Finance & Treasurer) as Vice President & Chief Financial Officer.
Shareholder Meeting Results
The holders of over 90% of Noven’s common
stock were represented in person or by proxy at the meeting, held May
14 at the company’s headquarters in Miami Florida. Shareholders re-elected
the following persons to the Noven Board of Directors:
- Sidney Braginsky (President & CEO of Atropos Technology Inc.);
- John G. Clarkson, M.D. (Senior Vice President for Medical Affairs & Dean,
University of Miami School of Medicine);
- Lawrence J. DuBow (Chairman, HMS Sales and Marketing, Inc.);
- Regina E. Herzlinger (Prof. of Business Administration, Harvard Business
School);
- Robert C. Strauss (President, CEO & Chairman of Noven); and
- Wayne P. Yetter (CEO & Chairman, SYNAVANT, Inc.).
Shareholders also ratified the appointment of Deloitte & Touche LLP as Noven's independent auditors for 2003. At the meeting, Robert Strauss made a presentation regarding Noven’s business and prospects. A replay of the meeting is available at www.noven.com.
Appointment of CFO
Noven also announced that its Board of Directors
has appointed Diane M. Barrett as Noven's Vice President & Chief
Financial Officer. Ms. Barrett, a Certified Public Accountant with over
20 years finance and accounting experience, joined Noven in August 2000,
and served most recently as Vice President – Finance & Treasurer.
She assumed the office of Chief Financial Officer from James B. Messiry.
Mr. Messiry has been appointed Senior Vice President, retaining responsibility
for the company’s transaction-related initiatives geared toward product
and partner diversification and other corporate objectives.
About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida,
is a leading developer of advanced transdermal drug delivery technologies
and prescription transdermal products. Together with Novartis Pharmaceuticals
Corporation, Noven owns a profitable women’s health products company
called Novogyne Pharmaceuticals. Noven’s existing products include advanced
estrogen transdermal delivery systems (including Vivelle-Dot®, licensed
to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination
estrogen/progestin transdermal delivery systems (including CombiPatch®,
licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG).
With a range of additional products in development, Noven is committed
to becoming the world’s premier transdermal drug delivery company.
Contact:
Investor & Media Contact
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916